Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature

  title={Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature},
  author={Marcia A. Ciccone and Asaf Maoz and Jennifer K. Casabar and Hiroko Machida and Seiji Mabuchi and Koji Matsuo},
  journal={Expert Opinion on Investigational Drugs},
  pages={781 - 796}
ABSTRACT Introduction: While serine-threonine kinases (STK) are attractive therapeutic targets in epithelial ovarian cancer, clinical outcomes of STK inhibitors in the management of recurrent disease have not been completely described. Areas covered: A systematic literature review of published clinical studies on STK inhibitors targeting mTOR, MAPK, and aurora kinase pathways in recurrent epithelial ovarian cancer was conducted, revealing 18 clinical trials (497 patients). Pooled analyses were… 
Emerging serine-threonine kinase inhibitors for treating ovarian cancer
Serine threonine kinases (STKs) have been proposed as potential therapeutic targets in ovarian cancer because of their role in the initiation and progression of cancers and have modest activity as single agents and are unlikely to achieve approval as monotherapy for unselected ovarian cancer patients.
Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord–Stromal Tumors: A Contemporary Review
The rarity and complexity of non-epithelial ovarian tumors warrant collaboration and efficient clinical trial design, including high-quality molecular characterization, to guide future efforts.
Rare ovarian tumours. Other treatments for ovarian cancer
Ovarian Epithelial Carcinogenesis
The current chapter will focus on the cell origin, pathogenesis, molecular genetics, and clinical applications of different EOC histological subtypes to improve the understanding of this deadly disease.
Characterization of the Potential Role of NTPCR in Epithelial Ovarian Cancer by Integrating Transcriptomic and Metabolomic Analysis
It is demonstrated that DEGs and differential metabolites were mainly related to several signaling pathways, which might be a crucial role in the progression of NTPCR regulation of EOC.
Clinical Significance and Prognostic Value of Lactate Dehydrogenase Expression in Cervical Cancer.
Elevated LDH expression levels were associated with poor overall survival in CC patients, suggesting LDH upregulation might serve as a therapeutic and prognostic biomarker for CC.
Natural Compounds and Derivatives as Ser/Thr Protein Kinase Modulators and Inhibitors
The search for small-molecule inhibitors targeting the altered protein kinase molecules in tumour cells has become a major research focus in the academia and pharmaceutical companies.
Discovery of metabolomic biomarkers for discriminating platinum-sensitive and platinum-resistant ovarian cancer by using GC-MS
This study aims to determine ovarian cancer patients with platinum resistance for alternative treatment protocols by using metabolomic methodologies using GC-MS to identify the biomarkers that cause differences between two groups.
The role of the globular heads of the C1q receptor in paclitaxel-induced human ovarian cancer cells apoptosis by a mitochondria-dependent pathway
Data support a mechanism that gC1qR-induced mitochondria dysfunction was involved in the paclitaxel-mediated apoptosis of ovarian cancer cells.
Radiotherapy for isolated recurrent epithelial ovarian cancer: A single institutional experience
The objective was to evaluate the efficacy and toxicity of external beam radiotherapy for isolated recurrent epithelial ovarian cancer (EOC) and to establish a protocol for this type of treatment.


Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
  • D. Matei, M. Sill, M. Birrer
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
Sorafenib has modest antitumor activity in patients with recurrent ovarian cancer, but the activity was at the expense of substantial toxicity.
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
  • F. Janku, J. Wheler, R. Kurzrock
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
A subset of patients with ovarian cancer with simultaneous PIK3CA and MAPK mutations responded to PI3K/AKT/mTOR inhibitors, suggesting that not all patients demonstrate resistance when the MAPK pathway is concomitantly activated.
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer
The addition of sorafenib to carboplatin/paclitaxel chemotherapy was not feasible within this neoadjuvant regimen in primary advanced ovarian cancer, and a detrimental effect of preoperative study medication could not be denied.
Overcoming platinum resistance in ovarian carcinoma
Analysis of recent clinical trials showed that gemcitabine-based combination chemotherapy was associated with the highest antitumor effects in platinum-resistant ovarian cancer patients during the study period.
Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium
This trial of gemcitabine and sorafenib in recurrent EOC did not meet its primary efficacy end point, but the combination was associated with encouraging rates of prolonged stable disease and CA-125 response.